PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Category:
Sort By:
Jun 06, 2023
Jun 06, 2023

bybhenderson

Dalton, Ohio, June 6, 2023 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced the submission of a research paper describing cell characterization, graft...Read more
May 04, 2023
Regenerative medicine has had a growing interest in health care, in the past several decades. This type of treatment focuses on engineering tissue to repair, restore and regenerate cells with...Read more
Jan 20, 2023
Patients with progressive degenerative eyesight, have been waiting for a cure. For years retinal replacement has been nothing but a wish. But with protoKinetix (PKTX) lives can be changed. PKTX...Read more
Marietta, Ohio, July 20, 2022 – ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that the University of Alberta has successfully completed Phase...Read more
Jul 15, 2022
We risk skin damage every time we step into the sun, whether for work, play, or travel. The sun’s UV rays cause inflammation and sunburns, and sustained damage can lead...Read more
Jun 27, 2022
Jun 27, 2022

byprotokinetixp

Advancements in medical science are making effective treatments more accessible than ever before. In its development of AAGP®, ProtoKinetix is opening the door to new cell therapies, as well as...Read more
Apr 19, 2022
The world over, there is increased interest in the possibility of extending human longevity. What could our lives look like if we had more control over our cells? If we...Read more
Marietta, Ohio, January 14, 2022- ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it will hold its Annual General Meeting of the...Read more
Jan 14, 2022
Investors in ProtoKinetix, Inc., are invited to attend the annual shareholder meeting at 4 p.m. EST on Feb. 11, 2022. Join the meeting online at http://www.virtualshareholdermeeting.com/PKTX2022.
Marietta, Ohio, November 23, 2021 – ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it has selected two formulations of its Anti-Aging...Read more
Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.

Picture of a molecule
Picture of a molecule